Table 1.

Outcome of TP53-mutated myeloid malignancies patients treated with intensive chemotherapy. CR: Complete Remission, EFS: Event Free Survival, OS: Overall Survival.

Regimen	Demographics	CR	EFS	OS	References
Cytarabine + anthracycline (7 + 3) and CPX 351	18–85 y/o	28–48%	3 years EFS 1–6%	3 years OS 3–8%	[16,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33]